Posted on

On May 3, 2023, Eli Lilly and Company announced in a press release that their Alzheimer’s drug, donanemab, successfully slowed cognitive decline in a Phase 3 trial that included individuals with early symptomatic Alzheimer’s disease. According to their statement, the company is seeking for the “fastest path to traditional approvals” and will apply for FDA approval of this drug as soon as possible.In the trial, the investigators evaluated treatment efficacy using the integrated Alzheimer’s Disease Rating Scale (iADRS). This metric takes cognition and a person’s ability to perform common daily activities into account, like driving, having hobbies, knowledge of current events, or managing finances.

Leave a Reply

Your email address will not be published. Required fields are marked *